In contrast to the wealth of proven therapies for heart failure with reduced ejection fraction
(HFrEF), therapeutic efforts in the past have failed to improve outcomes in heart failure with …

The management of heart failure with reduced ejection fraction (HF-REF) has improved
significantly over the last two decades. In contrast, little or no progress has been made in …

Heart failure with preserved ejection fraction (HFpEF) is a common clinical syndrome
associated with high rates of morbidity and mortality. Due to the lack of evidence-based …

Heart failure with preserved ejection fraction (HFpEF) is a growing epidemiologic problem
affecting more than half of the patients with heart failure (HF). HFpEF has a significant …

Approximately half of all patients with heart failure have preserved ejection fraction (HFpEF)
and, as life expectancies continue to increase in western societies, the prevalence of HFpEF …

It is estimated that half of all patients with heart failure (HF) have HF with preserved ejection
fraction (HFpEF). Yet this form of HF remains a diagnostic and therapeutic challenge …

Although patients with heart failure with preserved ejection fraction (HFpEF)(left ventricular
ejection fraction≥ 50%) comprise nearly half of those with chronic heart failure, evidence …

The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is
projected to worsen. To date, there are no approved therapies available for reducing …

Heart failure with preserved ejection fraction (HFpEF) represents a complex and
heterogeneous clinical syndrome, which is increasingly prevalent and associated with poor …

Over the last several decades, clinicians and clinical scientists have had growing interest in
heart failure (HF) diagnosis and treatment. While HF with reduced ejection fraction (EF) is a …